Cargando…

Physicians’ perspectives on the treatment of osteoporosis patients with bisphosphonates

BACKGROUND: Noncompliance with bisphosphonate therapy among osteoporosis patients attenuates the reduction of fracture risk. The objective of this study was to assess physicians’ prescribing considerations, preferences for osteoporosis treatments, and perceptions of patients’ compliance with oral bi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gu, Tao, Eisenberg Lawrence, Debra F, Stephenson, Judith J, Yu, Jingbo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4760663/ https://www.ncbi.nlm.nih.gov/pubmed/26929609 http://dx.doi.org/10.2147/CIA.S97593

Ejemplares similares

Bisphosphonates adherence for treatment of osteoporosis
por: Vieira, Helena Parente, et al.
Publicado: (2013)

A reappraisal of generic bisphosphonates in osteoporosis
por: Kanis, J. A., et al.
Publicado: (2011)

Long-term use of bisphosphonates in osteoporosis
por: Alwahhabi, Basmah K., et al.
Publicado: (2017)

Differences between the bisphosphonates for the prevention and treatment of osteoporosis
por: Grey, Andrew, et al.
Publicado: (2006)

Novel formulations of oral bisphosphonates in the treatment of osteoporosis
por: Fuggle, Nicholas, et al.
Publicado: (2022)

Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis
por: Pazianas, Michael, et al.
Publicado: (2010)

Intravenous bisphosphonates for postmenopausal osteoporosis
por: Mottaghi, Peyman
Publicado: (2010)

Bisphosphonates and glucocorticoid-induced osteoporosis: cons
por: Lems, Willem F., et al.
Publicado: (2015)

Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis
por: Cotté, F.-E., et al.
Publicado: (2009)

Patient preference in the management of postmenopausal osteoporosis with bisphosphonates
por: Reginster, Jean-Yves, et al.
Publicado: (2006)

Correction: Novel formulations of oral bisphosphonates in the treatment of osteoporosis
por: Fuggle, Nicholas, et al.
Publicado: (2023)

The therapeutic effect to eldecalcitol + bisphosphonate is superior to bisphosphonate alone in the treatment of osteoporosis: a meta-analysis
por: Zheng, Zaoqian, et al.
Publicado: (2020)

Can Alarming Improve Compliance with Weekly Bisphosphonate in Patients with Osteoporosis?
por: Nho, Jae-Hwi, et al.
Publicado: (2016)

Long-term use of bisphosphonates in osteoporosis
por: Sadat-Ali, Mir, et al.
Publicado: (2017)

Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk
por: Newcomb, P A, et al.
Publicado: (2010)

Osteonecrosis of the jaw in a patient under treatment of osteoporosis with oral bisphosphonate
por: Figueiredo, Marília A., et al.
Publicado: (2020)

Correction to: The therapeutic effect to eldecalcitol + bisphosphonate is superior to bisphosphonate alone in the treatment of osteoporosis: a meta-analysis
por: Zheng, Zaoqian, et al.
Publicado: (2020)

Bisphosphonates as treatment of secondary osteoporosis in children: a case series
por: Soesanti, Frida, et al.
Publicado: (2015)

Controversies in the treatment of postmenopausal osteoporosis: How long to treat with bisphosphonates?
por: Bandeira, Francisco, et al.
Publicado: (2020)

Additive effects of eldecalcitol in poorly responding long-term bisphosphonate treatment for osteoporosis
por: Kamimura, Mikio, et al.
Publicado: (2019)

Bisphosphonate use for glucocorticoid-induced osteoporosis in older patients with immune thrombocytopenia: a clinical perspective
por: Yamasaki, Satoshi
Publicado: (2023)

Compliance and persistence with oral bisphosphonates for the treatment of osteoporosis in female patients with rheumatoid arthritis
por: Park, Ji-Heh, et al.
Publicado: (2017)

Osteoporosis and Bisphosphonate-Related Osteonecrosis of the Jaw Bone
por: Villa, Alessandro, et al.
Publicado: (2011)

ERT, HRT, Raloxifine, Calcitonin, or Bisphosphonates for Osteoporosis
por: Curtiss, Frederic R.
Publicado: (2003)

Influence on persistence and adherence with oral bisphosphonates on fracture rates in osteoporosis
por: Höer, Ariane, et al.
Publicado: (2009)

Ibandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosis
por: Bauss, Frieder, et al.
Publicado: (2006)

Position Statement: Drug Holiday in Osteoporosis Treatment with Bisphosphonates in South Korea
por: Lee, Seung Hun, et al.
Publicado: (2015)

The effect of low-dose intravenous bisphosphonate treatment on osteoporosis in children with quadriplegic cerebral palsy
por: Moon, Soon Jeong, et al.
Publicado: (2017)

Dose-Intensity of Bisphosphonates and the Risk of Osteonecrosis of the Jaw in Osteoporosis Patients
por: Jung, Sung-mok, et al.
Publicado: (2018)

Effects of denosumab versus teriparatide in glucocorticoid-induced osteoporosis patients with prior bisphosphonate treatment
por: Hirooka, Yasuaki, et al.
Publicado: (2020)

Cost of non-persistence with oral bisphosphonates in post-menopausal osteoporosis treatment in France
por: Cotté, François-Emery, et al.
Publicado: (2011)

Atypical Femoral Fracture Combined with Osteonecrosis of Jaw During Osteoporosis Treatment with Bisphosphonate
por: Won, Yougun, et al.
Publicado: (2014)

Bone metabolism genes variation and response to bisphosphonate treatment in women with postmenopausal osteoporosis
por: Marozik, Pavel, et al.
Publicado: (2019)

1097. Is Early Bisphosphonate Treatment Safe or Effective for Pyogenic Vertebral Osteomyelitis With Osteoporosis?
por: Kim, Jihye, et al.
Publicado: (2018)

Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates
por: Miller, P. D., et al.
Publicado: (2016)

Optimizing dosing frequencies for bisphosphonates in the management of postmenopausal osteoporosis: patient considerations
por: Sunyecz, John
Publicado: (2008)

The relationship between bisphosphonate use and demographic characteristics of male osteoporosis patients
por: Cevikoi, Alev, et al.
Publicado: (2011)

Effects of Bisphosphonate on Osteocyte Proliferation and Bone Formation in Patients with Diabetic Osteoporosis
por: Weng, Beifang, et al.
Publicado: (2022)

Bone Quality and Fractures in Women With Osteoporosis Treated With Bisphosphonates for 1 to 14 Years
por: Malluche, Hartmut H, et al.
Publicado: (2021)

Bisphosphonates for the Prevention and Treatment of Osteoporosis in Patients with Rheumatic Diseases: A Systematic Review and Meta-Analysis
por: Feng, Zhiyun, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ndq31q20o2ojk8kmfbttppvbad